The California Hurdle - SB 790 and Pharma

This article reviews the changes SB 790 calls for, and what compliance professionals should keep an eye on. The California Senate passed a bill (“SB 790”) in May 2017 that, if enacted, will change how pharmaceutical companies interact with health care professionals (“HCPs”). While standards and requirements for transfers of value are not new to pharmaceutical companies, SB 790 introduces new concepts for California, including: • new standards for ‘allowable expenditures,’ which includes limitations on sponsorship of conferences or seminars that are educational, policy making, medical, or scientific; To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In       Related StoriesEffectiveness, The Holy Grail of Compliance - Both the DOJ & OIG Weigh InThis is Not Your Parent’s Compliance Program – The New Era of Compliance Resourcing at Small to Mid-Size Pharmaceutical CompaniesThe Ohio “Drug Price Relief Act” Has Some Enemies 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs